120 related articles for article (PubMed ID: 23857704)
1. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
3. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
4. BRCA2 mutation carriers, reproductive factors and breast cancer risk.
Tryggvadottir L; Olafsdottir EJ; Gudlaugsdottir S; Thorlacius S; Jonasson JG; Tulinius H; Eyfjord JE
Breast Cancer Res; 2003; 5(5):R121-8. PubMed ID: 12927042
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
6. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
[TBL] [Abstract][Full Text] [Related]
7. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
9. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
[TBL] [Abstract][Full Text] [Related]
11. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
12. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
14. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
15. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
17. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
19. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]